Current partner codePEPTIDESDE
NCT07423156·Phase 3·INTERVENTIONAL

Tranexamic Acid vs Vasopressin in Placenta Previa Trial

Status

Not yet recruiting

Phase

Phase 3

Enrollment

58

Locations

1

Results

Not posted

Publications

2

Study summary

What the protocol is testing.

Placenta previa is a major obstetric condition associated with increased risk of excessive blood loss during cesarean section, leading to maternal morbidity and mortality. Different pharmacological agents have been used to minimize intraoperative hemorrhage. Tranexamic acid is an antifibrinolytic agent, while vasopressin reduces blood loss by causing vasoconstriction and myometrial contraction at the injection site. Both drugs have been used separately in placenta previa cases, however direct comparison between tranexamic acid and vasopressin is limited. This randomized controlled trial will be conducted at the Department of Obstetrics \& Gynecology, AIMC/Jinnah Hospital Lahore. A total of 58 women (29 in each group), aged 18-45 years, with singleton pregnancy and diagnosed placenta previa undergoing elective cesarean section will be included. Participants will be randomly allocated into two groups. Group A will receive 1 gram tranexamic acid diluted in 20 ml of 5% dextrose intravenously 15 minutes before cesarean section. Group B will receive 4 units vasopressin diluted in 20 ml normal saline injected at placental implantation site after delivery of placenta. The primary outcome will be intraoperative blood loss measured by gauze saturation assessment and suction drain measurement. The study will help determine which drug is more effective in reducing blood loss in placenta previa patients undergoing cesarean section.

Full detailed description

This study is a randomized controlled trial designed to compare the efficacy of tranexamic acid versus vasopressin in reducing intraoperative blood loss among patients with placenta previa undergoing elective cesarean section. The study will be conducted in the Department of Obstetrics \& Gynecology, Allama Iqbal Medical College (AIMC)/Jinnah Hospital, Lahore, over a maximum duration of 12 months after approval of synopsis. A total sample size of 58 patients will be enrolled through non-probability purposive sampling. Women aged 18-45 years with singleton pregnancy and placenta previa scheduled for elective cesarean section will be included. Patients undergoing emergency cesarean section, having coagulation disorders, chronic liver/kidney disease, gestational diabetes, hypertensive disorders of pregnancy, history of postpartum hemorrhage, or using anticoagulant/antiplatelet drugs will be excluded. After informed consent, baseline characteristics including age, gravida, para, abortion history, grade of placenta previa, and pre-operative hemoglobin will be recorded. Patients will be randomized into two groups using paper lottery method. Group A will receive injection tranexamic acid 1 gram diluted in 20 ml of 5% dextrose administered intravenously 15 minutes before cesarean section. Group B will receive injection vasopressin 4 units diluted in 20 ml normal saline injected at placental implantation site after delivery of placenta. Both groups will receive standard uterotonic management with oxytocin 40 units in 500 ml of 5% glucose solution. Blood loss will be assessed intraoperatively using visual gauze saturation method and suction drain volume. Post-operative hematocrit will be measured after achieving hemostasis and closure. Data will be analyzed using SPSS(statistical package of social sciences) version 26. Quantitative variables will be expressed as mean ± standard deviation and categorical variables as frequency and percentage. Independent sample t-test or Mann Whitney U test will be applied for comparison of quantitative variables, and Chi-square test for categorical variables. Stratification will be done for age and grade of placenta previa. A p-value ≤ 0.05 will be considered statistically significant. The findings will help identify which intervention is more effective and safer for reducing intraoperative blood loss in placenta previa patients undergoing cesarean section.

Interventions

Treatment arms and agents.

DRUG

Group A: Tranexamic acid

Injection Tranexamic Acid 1 gram diluted in 20 mL of 5% dextrose will be administered intravenously 15 minutes before cesarean section. (prophylactically)

DRUG

Group B: Vasopressin

Injection Vasopressin 4 units diluted in 20 mL of normal saline will be injected locally at the placenta implantation site after delivery of placenta.

Timeline

From registration to results.

  1. First posted

    Feb 20, 2026

  2. Study start

    Mar 1, 2026

  3. Primary completion

    Aug 31, 2026

  4. Study completion

    Aug 31, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Feb 20, 2026

Outcomes

What the study measures.

Primary outcomes

Intraoperative Blood Loss

Time frame · Assessed intraoperatively (during cesarean section) and finalized once postoperative hematocrit is available immediately after surgery.

Total estimated blood loss during cesarean section measured using the per-operative visual assessment method (gauze saturation method) plus the amount of blood collected in the suction drain.

Secondary outcomes

Need for Blood Transfusion

Time frame · Assessed within the immediate postoperative period (after surgery).

Requirement of blood transfusion if postoperative hemoglobin is \< 9 g/dL.

Drug Efficacy

Time frame · Assessed intraoperatively at completion of surgery.

Drug will be considered efficacious if estimated intraoperative blood loss is ≤ 500 mL.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
45 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: Women of reproductive age Age 18-45 years Diagnosed placenta previa in current pregnancy Scheduled for elective cesarean section Singleton pregnancy Exclusion Criteria: Emergency cesarean section Platelet or coagulation disorder Use of anti-platelet or anti-coagulant drugs Previous history of postpartum hemorrhage Chronic liver disease Chronic kidney disease Gestational diabetes Pregnancy-related hypertensive disorders \-

Study locations

1 registered sites.

Pakistan. Showing up to 24 locations stored in the fast local snapshot.

Jinnah Hospital

Lahore, Punjab Province, Pakistan

Related trials

More studies on Vasopressin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.